KPTI
Karyopharm Therapeutics Inc.
Price Chart
Latest Quote
$9.46
+0.37 (+4.07%)
Current Price
| Previous Close | $9.09 |
| Open | $9.08 |
| Day High | $9.65 |
| Day Low | $9.01 |
| Volume | 439,751 |
Stock Information
| Shares Outstanding | 22.66M |
| Total Debt | $303.21M |
| Cash Equivalents | $90.85M |
| Revenue | $151.12M |
| Net Income | $-194.97M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $214.39M |
| EPS (TTM) | $-16.40 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $426.75M |
| Sales | $151.12M |
| Income | $-194.97M |
| Book/sh | $-11.78 |
| Cash/sh | $4.01 |
| Employees | 228 |
Financial Ratios
| Quick Ratio | 0.97 |
| Current Ratio | 1.08 |
Returns & Margins
| ROA | -40.62% |
| Gross Margin | 13.45% |
| Operating Margin | -76.31% |
| Profit Margin | -129.02% |
Ownership
| Insider Ownership | 4.68% |
| Institutional Ownership | 83.69% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.93 |
| P/S | 1.42 |
| P/B | -0.80 |
Analyst Data
| Recommendation | buy |
| Target Price | $13.50 |
Technical Indicators
| SMA20 | $9.18 |
| SMA50 | $8.85 |
| SMA200 | $7.33 |
| RSI | 54.14 |
| ATR | 0.7071 |
| Shares Float | 14.81M |
| Short Float | 23.72% |
| Short Ratio | 12.00 |
| Volatility | 0.82 |
| Rel Volume | 1.23 |
Performance History
| Week | +0.64% |
| Month | +5.46% |
| Quarter | +81.57% |
| 6 Months | +30.12% |
| YTD | +31.57% |
| Year | +103.44% |
| 3 Years | -69.53% |
| 5 Years | -93.99% |
| 10 Years | -90.67% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $9.46 | 439,751 |
| 2026-06-24 | $9.12 | 351,900 |
| 2026-06-23 | $9.65 | 712,000 |
| 2026-06-22 | $9.00 | 356,300 |
| 2026-06-18 | $9.02 | 491,900 |
| 2026-06-17 | $9.40 | 283,600 |
| 2026-06-16 | $9.10 | 322,100 |
| 2026-06-15 | $9.64 | 172,500 |
| 2026-06-12 | $9.50 | 564,600 |
| 2026-06-11 | $9.00 | 200,300 |
| 2026-06-10 | $9.11 | 284,900 |
| 2026-06-09 | $8.69 | 324,100 |
| 2026-06-08 | $8.50 | 260,200 |
| 2026-06-05 | $9.08 | 262,500 |
| 2026-06-04 | $9.07 | 219,100 |
| 2026-06-03 | $9.00 | 499,700 |
| 2026-06-02 | $9.23 | 583,800 |
| 2026-06-01 | $9.82 | 330,000 |
| 2026-05-29 | $9.10 | 290,700 |
| 2026-05-28 | $9.11 | 179,200 |
| 2026-05-27 | $8.98 | 624,400 |
| 2026-05-26 | $8.97 | 570,500 |
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
đ° Latest News
Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update
Simply Wall St. âĸ 2026-06-25T12:06:45Z
How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI)
Simply Wall St. âĸ 2026-06-07T11:06:54Z
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet
Zacks âĸ 2026-05-27T13:55:01Z
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts
MarketBeat âĸ 2026-05-26T12:04:55Z
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus
MarketBeat âĸ 2026-05-26T11:06:37Z
Karyopharm Therapeutics Inc (KPTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
GuruFocus.com âĸ 2026-05-14T23:04:11ZKaryopharm Therapeutics Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-14T21:19:04Z
Karyopharm Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-14T17:09:59Z
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-14T12:45:04Z
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-12T21:15:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,949,000 | $6,007,000 | $4,942,000 | $5,213,000 |
| Cost Of Revenue | $5,949,000 | $6,007,000 | $4,942,000 | $5,213,000 |
| Total Revenue | $146,067,000 | $145,237,000 | $146,033,000 | $157,074,000 |
| Operating Revenue | $146,067,000 | $145,237,000 | $146,033,000 | $157,074,000 |
| Expenses | ||||
| Interest Expense | $45,849,000 | $37,422,000 | $23,823,000 | $24,996,000 |
| Total Expenses | $236,774,000 | $264,680,000 | $275,573,000 | $299,276,000 |
| Other Income Expense | $-62,213,000 | $73,100,000 | $-356,000 | $-83,000 |
| Other Non Operating Income Expenses | $152,000 | $28,398,000 | $-356,000 | $-83,000 |
| Net Non Operating Interest Income Expense | $-43,076,000 | $-30,022,000 | $-12,880,000 | $-22,637,000 |
| Interest Expense Non Operating | $45,849,000 | $37,422,000 | $23,823,000 | $24,996,000 |
| Operating Expense | $230,825,000 | $258,673,000 | $270,631,000 | $294,063,000 |
| General And Administrative Expense | $105,208,000 | $115,441,000 | $131,881,000 | $145,401,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-196,039,000 | $-76,422,000 | $-143,099,000 | $-165,291,000 |
| Net Interest Income | $-43,076,000 | $-30,022,000 | $-12,880,000 | $-22,637,000 |
| Interest Income | $2,773,000 | $7,400,000 | $10,943,000 | $2,359,000 |
| Normalized Income | $-146,770,650 | $-111,736,580 | $-143,099,000 | $-165,291,000 |
| Net Income From Continuing And Discontinued Operation | $-196,039,000 | $-76,422,000 | $-143,099,000 | $-165,291,000 |
| Total Operating Income As Reported | $-90,707,000 | $-119,443,000 | $-129,540,000 | $-142,202,000 |
| Net Income Common Stockholders | $-196,039,000 | $-76,422,000 | $-143,099,000 | $-165,291,000 |
| Net Income | $-196,039,000 | $-76,422,000 | $-143,099,000 | $-165,291,000 |
| Net Income Including Noncontrolling Interests | $-196,039,000 | $-76,422,000 | $-143,099,000 | $-165,291,000 |
| Net Income Continuous Operations | $-196,039,000 | $-76,422,000 | $-143,099,000 | $-165,291,000 |
| Pretax Income | $-195,996,000 | $-76,365,000 | $-142,776,000 | $-164,922,000 |
| Special Income Charges | $-62,365,000 | $44,702,000 | $0 | $0 |
| Interest Income Non Operating | $2,773,000 | $7,400,000 | $10,943,000 | $2,359,000 |
| Operating Income | $-90,707,000 | $-119,443,000 | $-129,540,000 | $-142,202,000 |
| Gross Profit | $140,118,000 | $139,230,000 | $141,091,000 | $151,861,000 |
| Per Share | ||||
| Diluted EPS | $-17.93 | $-13.95 | $-18.79 | $-30.30 |
| Basic EPS | $-17.93 | $-9.45 | $-18.79 | $-30.30 |
| Other | ||||
| Tax Effect Of Unusual Items | $-13,096,650 | $9,387,420 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-87,486,000 | $-83,305,000 | $-118,423,000 | $-139,305,000 |
| Total Unusual Items | $-62,365,000 | $44,702,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-62,365,000 | $44,702,000 | $0 | $0 |
| Reconciled Depreciation | $296,000 | $340,000 | $530,000 | $621,000 |
| EBITDA (Bullshit earnings) | $-149,851,000 | $-38,603,000 | $-118,423,000 | $-139,305,000 |
| EBIT | $-150,147,000 | $-38,943,000 | $-118,953,000 | $-139,926,000 |
| Diluted Average Shares | $10,935,000 | $8,453,933 | $7,616,000 | $5,458,066 |
| Basic Average Shares | $10,935,000 | $8,124,200 | $7,616,000 | $5,458,066 |
| Diluted NI Availto Com Stockholders | $-196,039,000 | $-76,422,000 | $-143,099,000 | $-165,291,000 |
| Tax Provision | $43,000 | $57,000 | $323,000 | $369,000 |
| Other Special Charges | $62,365,000 | $-44,702,000 | - | - |
| Research And Development | $125,617,000 | $143,232,000 | $138,750,000 | $148,662,000 |
| Selling General And Administration | $105,208,000 | $115,441,000 | $131,881,000 | $145,401,000 |
| Other Gand A | $43,864,000 | $44,371,000 | $50,606,000 | $56,412,000 |
| Salaries And Wages | $61,344,000 | $71,070,000 | $81,275,000 | $88,989,000 |
| Gain On Sale Of Security | - | - | - | $-96,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-292,926,000 | $-186,017,000 | $-136,206,000 | $-16,656,000 |
| Total Assets | $108,416,000 | $164,418,000 | $240,438,000 | $358,172,000 |
| Total Non Current Assets | $5,270,000 | $7,956,000 | $6,517,000 | $8,010,000 |
| Other Non Current Assets | $618,000 | $1,672,000 | $1,635,000 | $633,000 |
| Current Assets | $103,146,000 | $156,462,000 | $233,921,000 | $350,162,000 |
| Other Current Assets | $9,186,000 | $12,245,000 | $11,813,000 | $19,821,000 |
| Inventory | $4,038,000 | $4,739,000 | $3,043,000 | $4,224,000 |
| Receivables | $26,178,000 | $30,766,000 | $26,962,000 | $47,086,000 |
| Accounts Receivable | $26,178,000 | $30,766,000 | $26,962,000 | $47,086,000 |
| Cash Cash Equivalents And Short Term Investments | $63,744,000 | $108,712,000 | $191,443,000 | $277,967,000 |
| Cash And Cash Equivalents | $60,540,000 | $62,476,000 | $52,231,000 | $135,188,000 |
| Restricted Cash | - | $30,000 | $660,000 | $1,064,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $166,355,000 | $124,898,000 | $118,688,000 | $34,917,000 |
| Total Debt | $233,607,000 | $194,524,000 | $177,016,000 | $179,074,000 |
| Long Term Debt And Capital Lease Obligation | $211,628,000 | $169,660,000 | $173,708,000 | $176,202,000 |
| Long Term Debt | $205,885,000 | $162,948,000 | $170,919,000 | $170,105,000 |
| Current Debt And Capital Lease Obligation | $21,979,000 | $24,864,000 | $3,308,000 | $2,872,000 |
| Current Debt | $21,010,000 | $24,426,000 | - | - |
| Other Current Borrowings | $21,010,000 | $24,426,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $401,342,000 | $350,435,000 | $376,644,000 | $374,828,000 |
| Total Non Current Liabilities Net Minority Interest | $309,282,000 | $258,171,000 | $307,165,000 | $308,920,000 |
| Other Non Current Liabilities | $11,095,000 | $2,430,000 | $978,000 | - |
| Derivative Product Liabilities | $14,221,000 | $12,582,000 | $0 | - |
| Non Current Deferred Liabilities | $72,338,000 | $73,499,000 | $132,479,000 | $132,718,000 |
| Current Liabilities | $92,060,000 | $92,264,000 | $69,479,000 | $65,908,000 |
| Other Current Liabilities | $1,580,000 | $1,641,000 | $1,654,000 | $1,848,000 |
| Payables And Accrued Expenses | $64,122,000 | $51,844,000 | $48,007,000 | $41,563,000 |
| Interest Payable | $10,344,000 | $1,857,000 | $13,454,000 | $11,673,000 |
| Payables | $4,003,000 | $5,107,000 | $3,123,000 | $2,773,000 |
| Accounts Payable | $4,003,000 | $5,107,000 | $3,123,000 | $2,773,000 |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-292,926,000 | $-186,017,000 | $-136,206,000 | $-16,656,000 |
| Total Equity Gross Minority Interest | $-292,926,000 | $-186,017,000 | $-136,206,000 | $-16,656,000 |
| Stockholders Equity | $-292,926,000 | $-186,017,000 | $-136,206,000 | $-16,656,000 |
| Gains Losses Not Affecting Retained Earnings | $71,000 | $-356,000 | $-161,000 | $-638,000 |
| Other Equity Adjustments | $71,000 | $-356,000 | $-161,000 | $-638,000 |
| Retained Earnings | $-1,759,499,000 | $-1,563,460,000 | $-1,487,038,000 | $-1,343,939,000 |
| Other | ||||
| Ordinary Shares Number | $18,311,307 | $8,413,400 | $7,661,000 | $7,547,533 |
| Share Issued | $18,311,307 | $8,413,400 | $7,661,000 | $7,547,533 |
| Tangible Book Value | $-292,926,000 | $-186,017,000 | $-136,206,000 | $-16,656,000 |
| Invested Capital | $-66,031,000 | $1,357,000 | $34,713,000 | $153,449,000 |
| Working Capital | $11,086,000 | $64,198,000 | $164,442,000 | $284,254,000 |
| Capital Lease Obligations | $6,712,000 | $7,150,000 | $6,097,000 | $8,969,000 |
| Total Capitalization | $-87,041,000 | $-23,069,000 | $34,713,000 | $153,449,000 |
| Additional Paid In Capital | $1,466,488,000 | $1,377,786,000 | $1,350,981,000 | $1,327,909,000 |
| Capital Stock | $14,000 | $13,000 | $12,000 | $12,000 |
| Common Stock | $14,000 | $13,000 | $12,000 | $12,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $5,743,000 | $6,712,000 | $2,789,000 | $6,097,000 |
| Current Capital Lease Obligation | $969,000 | $438,000 | $3,308,000 | $2,872,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,379,000 | $13,915,000 | $16,510,000 | $19,625,000 |
| Current Accrued Expenses | $60,119,000 | $46,737,000 | $44,884,000 | $38,790,000 |
| Net PPE | $4,652,000 | $6,284,000 | $4,882,000 | $7,377,000 |
| Accumulated Depreciation | $-5,510,000 | $-6,691,000 | $-6,565,000 | $-6,645,000 |
| Gross PPE | $10,162,000 | $12,975,000 | $11,447,000 | $14,022,000 |
| Leases | $3,401,000 | $4,878,000 | $4,878,000 | $5,451,000 |
| Other Properties | $5,520,000 | $6,856,000 | $5,106,000 | $7,108,000 |
| Machinery Furniture Equipment | $1,241,000 | $1,241,000 | $1,463,000 | $1,463,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $430,000 | $477,000 | $758,000 | $976,000 |
| Work In Process | $2,980,000 | $3,542,000 | $1,732,000 | $1,878,000 |
| Raw Materials | $628,000 | $720,000 | $553,000 | $1,370,000 |
| Other Short Term Investments | $3,204,000 | $46,236,000 | $139,212,000 | $142,779,000 |
| Treasury Shares Number | - | - | $0 | - |
| Current Deferred Revenue | - | - | - | - |
| Investments And Advances | - | - | - | - |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-75,369,000 | $-127,628,000 | $-92,723,000 | $-149,672,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-75,369,000 | $-127,486,000 | $-92,723,000 | $-149,554,000 |
| Cash Flow From Continuing Operating Activities | $-75,369,000 | $-127,486,000 | $-92,723,000 | $-149,554,000 |
| Operating Gains Losses | $61,658,000 | $-73,393,000 | - | $-281,000 |
| Investing Activities | ||||
| Investing Cash Flow | $43,378,000 | $95,473,000 | $7,940,000 | $-104,256,000 |
| Cash Flow From Continuing Investing Activities | $43,378,000 | $95,473,000 | $7,940,000 | $-104,256,000 |
| Capital Expenditure | - | $-142,000 | - | $-118,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,750,000 | $0 | $0 | $189,761,000 |
| Financing Cash Flow | $30,048,000 | $41,646,000 | $1,124,000 | $193,738,000 |
| Cash Flow From Continuing Financing Activities | $30,048,000 | $41,646,000 | $1,124,000 | $193,738,000 |
| Net Other Financing Charges | $-6,463,000 | $-43,106,000 | - | - |
| Net Common Stock Issuance | $8,750,000 | $0 | $0 | $189,761,000 |
| Common Stock Issuance | $8,750,000 | $0 | $0 | $189,761,000 |
| Other | ||||
| Repayment Of Debt | $-250,000 | $0 | $0 | - |
| Issuance Of Debt | $27,250,000 | $83,300,000 | $0 | $0 |
| Interest Paid Supplemental Data | $14,379,000 | $38,595,000 | $21,228,000 | $34,448,000 |
| End Cash Position | $60,891,000 | $62,814,000 | $53,192,000 | $136,885,000 |
| Beginning Cash Position | $62,814,000 | $53,192,000 | $136,885,000 | $197,445,000 |
| Effect Of Exchange Rate Changes | $20,000 | $-11,000 | $-34,000 | $-488,000 |
| Changes In Cash | $-1,943,000 | $9,633,000 | $-83,659,000 | $-60,072,000 |
| Proceeds From Stock Option Exercised | $761,000 | $1,452,000 | $1,124,000 | $3,977,000 |
| Net Issuance Payments Of Debt | $27,000,000 | $83,300,000 | $0 | $0 |
| Net Long Term Debt Issuance | $27,000,000 | $83,300,000 | $0 | $0 |
| Long Term Debt Payments | $-250,000 | $0 | $0 | - |
| Long Term Debt Issuance | $27,250,000 | $83,300,000 | $0 | $0 |
| Net Investment Purchase And Sale | $43,378,000 | $95,615,000 | $7,940,000 | $-104,138,000 |
| Sale Of Investment | $43,378,000 | $154,437,000 | $167,091,000 | $121,878,000 |
| Purchase Of Investment | $0 | $-58,822,000 | $-159,151,000 | $-226,016,000 |
| Net PPE Purchase And Sale | $0 | $-142,000 | $0 | $-118,000 |
| Purchase Of PPE | $0 | $-142,000 | $0 | $-118,000 |
| Change In Working Capital | $28,272,000 | $-302,000 | $31,421,000 | $-19,989,000 |
| Change In Other Current Liabilities | $-438,000 | $1,053,000 | $-2,872,000 | $-2,316,000 |
| Change In Other Current Assets | $1,336,000 | $-1,608,000 | $1,962,000 | $1,677,000 |
| Change In Payables And Accrued Expense | $17,959,000 | $6,185,000 | $4,352,000 | $-8,366,000 |
| Change In Accrued Expense | $19,063,000 | $4,201,000 | $4,002,000 | $-9,536,000 |
| Change In Payable | $-1,104,000 | $1,984,000 | $350,000 | $1,170,000 |
| Change In Account Payable | $-1,104,000 | $1,984,000 | $350,000 | $1,170,000 |
| Change In Prepaid Assets | $4,126,000 | $-432,000 | $6,674,000 | $-5,782,000 |
| Change In Inventory | $701,000 | $-1,696,000 | $1,181,000 | $-118,000 |
| Change In Receivables | $4,588,000 | $-3,804,000 | $20,124,000 | $-5,084,000 |
| Changes In Account Receivables | $4,588,000 | $-3,804,000 | $20,124,000 | $-5,084,000 |
| Other Non Cash Items | $16,804,000 | $6,369,000 | $814,000 | $812,000 |
| Stock Based Compensation | $14,050,000 | $18,426,000 | $21,709,000 | $35,399,000 |
| Amortization Of Securities | $-410,000 | $-2,504,000 | $-4,098,000 | $-825,000 |
| Depreciation Amortization Depletion | $296,000 | $340,000 | $530,000 | $621,000 |
| Depreciation And Amortization | $296,000 | $340,000 | $530,000 | $621,000 |
| Gain Loss On Investment Securities | $-707,000 | $-28,691,000 | - | $-281,000 |
| Net Income From Continuing Operations | $-196,039,000 | $-76,422,000 | $-143,099,000 | $-165,291,000 |
| Net Intangibles Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Intangibles | - | - | $0 | $0 |
| Change In Other Working Capital | - | - | - | - |
| Asset Impairment Charge | - | - | - | - |
Fetched: 2026-06-22